Company intelligence / Profile preview

CanXida

Ownership: Private
Development stage: Commercial

Overview

CanXida’s products are commercially available globally. A gold-standard randomized double-blind placebo-controlled clinical trial of their lead product "CanXida Remove RMV" for candida overgrowth began in early 2024. The study aims to provide robust evidence of efficacy against symptoms such as vaginal complications and digestive disturbances. Results are pending as of June 2025.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Small molecule (natural compounds and extracts)Probiotic (live biotherapeutic product therapy)Enzyme-based supplement (enzyme replacement therapy)Multivitamin/mineral supplement (vitamin/mineral therapy)
Industry: Food & Nutrition

Drug pipeline

3 assets

CanXida Remove

Commercial

Indications: Candida infection, Bacterial infection, Parasitic infection

2 more assets in the full pipeline.

Request access →

Partnerships

Citruslabs – collaborative clinical research partner for the RMV formula trial

Beyond the preview

Go deeper on CanXida.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CanXida.

Explore the full profile